TITLE:
A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)

CONDITION:
Chronic Lymphocytic Leukemia

INTERVENTION:
OSI-461

SUMMARY:

      The objectives of this study are to evaluate the safety and efficacy of OSI-461 in CLL
      patients.
    

DETAILED DESCRIPTION:

      The primary objective of this study is to determine the activity of OSI-461 given twice
      daily orally in previously untreated CLL patients. The secondary objective is to evaluate
      the safety profile of OSI-461 in this patient population.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Diagnosis of CLL established by bone marrow aspiration and biopsy or flow cytometry
             of peripheral blood.

          -  No previous therapy for CLL.

          -  Expected remaining life span greater than or equal to six months.

          -  18 years or older.

          -  Willingness and ability to sign an informed consent.

        Exclusion Criteria:

          -  Other active malignancy or history of treatment of any malignancy (excluding
             non-melanoma skin cancer) within the previous three years.

          -  History of other malignancy which could affect the diagnosis or assessment of
             OSI-461.

          -  Previous therapy for CLL.

          -  Use of an investigational medication or device within one month of initiating study
             therapy.

          -  Concurrent immunotherapy.

          -  Use of steroids at the time of enrollment (patients who require steroids after
             enrollment may remain on study).

          -  Any condition or any medication which may interfere with the conduct of the study.

          -  Serious uncontrolled intercurrent medical or psychiatric illness, including serious
             infection.

          -  Evidence of CNS involvement.

          -  Pregnant or nursing women.
      
